PHESGO is a new combined fixed-dose subcutaneous (SC) formulation of pertuzumab and trastuzumab that requires just 20–38 minutes for administration and monitoring1


PHESGO is now NHS commissioned in England2, Northern Ireland and Wales
for patients with HER2-positive eBC and mBC

Early breast cancer (eBC):1 PHESGO is indicated for use in combination with chemotherapy in:
• The neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence
• The adjuvant treatment of adult patients with HER2-positive eBC at high risk of recurrence


Metastatic breast cancer (mBC):1 PHESGO is indicated for use in combination with docetaxel in adult patients with HER2-positive metastatic or locally recurrent
unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease


PHESGO produced non-inferior serum trough concentrations compared with PERJETA® (pertuzumab) IV and trastuzumab IV3

FeDeriCa study design

Serum trough concentration results

pCR rates


PHESGO had a safety profile which is consistent with that of PERJETA IV and trastuzumab IV1

Across indications

PHESGO can reduce administration and monitoring time by up to 92% compared with PERJETA IV and trastuzumab IV4

Preparation and dosing



Patient preference study

View a range of practical and informative resources for healthcare professionals and patients receiving PHESGO

Administration video

Dosing and administration guide

Patient information booklet

eBC, early breast cancer; IV, intravenous; mBC, metastatic breast cancer; pCR, pathological complete response.



  1. PHESGO Summary of Product Characteristics.
  2. NHS England Cancer Drugs Fund List. Available at [Accessed 24 February 2021]
  3. Tan AR et al. Lancet Oncol. 2021;22(1):85–97.
  4. Roche. Data on File. M-GB-00002430.


Date of preparation: February 2021.